ArticleOpen heart2026
Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMineralocorticoid receptor antagonists (MRAs) are core therapy in chronic heart failure (HF) and reduce all-cause mortality and sudden cardiac death. However, direct comparisons of spironolactone and eplerenone in the context of ventricular arrhythmia recurrence are lacking. This study aims to compare the effects of these two MRAs on all-cause mortality and recurrence of sustained monomorphic ventricular tachycardia (VT) in patients with HF.
methodsWe analysed data of HF patients with left ventricular ejection fraction (LVEF) below 50%, hospitalised for sustained monomorphic VT and receiving MRA therapy at discharge. We performed propensity score matching for 13 variables, including medical history, medication and arrhythmia presentation. The endpoints were all-cause mortality and VT recurrence.
resultsAmong the 292 patients who met the selection criteria, 202 were included in the final analysis after propensity score matching, representing 69% of the eligible cohort. Median age was 67 (61-74) years and 87% were male. The median LVEF was 30% (25%-35%). The median follow-up duration was 32 (18-36) months, with a minimum follow-up of 1 year. During follow-up, 70 patients died, while VT recurrence was observed in 86 patients. There was no significant difference in all-cause mortality between the two MRAs (HR 0.98 (0.62 to 1.57), p=0.94). However, eplerenone was associated with a significantly lower risk of VT recurrence compared with spironolactone (HR 0.42 (0.26 to 0.66), p<0.001, Fine-Gray adjusted HR 0.36 (0.22 to 0.59), p<0.001).
conclusionsIn HF patients with sustained monomorphic VT, eplerenone was associated with fewer VT recurrences than spironolactone, without differences in all-cause mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.